Amyloid testing request reveals model for aducanumab prescribing in early AD

The controversial anti-Alzheimers drug aducanumab may have just started the assessment process for TGA approval in Australia but there is already an application for public funding of the tests for amyloid positivity that will decide who is eligible for the drug if and when it is listed on the PBS. The Medicare Service Advisory Committee ...

Already a member?

Login to keep reading.

© 2021 the limbic